Dianthus Therapeutics, Inc. · NASDAQ:DNTH
Dianthus Therapeutics — Magenta Therapeutics — Merger or Acquisition (May 2023)
28 slides from Dianthus Therapeutics's merger presentation, May 3, 2023
Slide 1: Merger Announcement
Exhibit 99.2 Merger Announcement May 3, 2023
Slide 2: Agenda
Agenda | Merger Announcement Introductions & Steve Mahoney, President, Chief Financial and Operating Officer Transaction of Magenta Therapeutics Overview Dianthus Marino Garcia, President and Chief Executive Officer of Dianthus Overview Therapeutics DNTH103 Simrat Randhawa, M.D., Chief Medical Offic
Slide 3: Disclaimer: Forward Looking Statements
DISCLAIMER Forward Looking Statements Certain statements in this presentation (“Presentation”), other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the Unit
Slide 4: Disclaimer (continued): No Offer or Solicitation
DISCLAIMER (continued) No Offer or Solicitation This Presentation and the information contained herein, is not intended to and shall not constitute (i) a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed Transaction or (ii) an offer to buy or s
Slide 5: Merger is transformative for both Magenta and Dianthus with potential for significant value creation
Merger is transformative for both Magenta and Dianthus with potential for significant value creation • Dianthus Therapeutics opportunity: Provides Magenta stockholders with the opportunity to participate in the exciting Dianthus growth story at a pivotal time in its evolution with potential for sign
Slide 6: Merger of Dianthus and Magenta
Merger of Dianthus and Magenta • Merger with Dianthus Therapeutics, a privately-held next-generation complement biotech focused on severe autoimmune diseases • Supported by the Board of Directors of both companies and is subject to stockholder approval and other customary Overview closing conditions
Slide 7: Developing next-generation complement therapies
Developing next-generation complement therapies Founded in 2019 to develop next-generation complement therapies targeting severe autoimmune disorders Lead compound, DNTH103, is a potent monoclonal antibody that selectively targets $100M the active C1s protein, inhibiting only the classical complemen
Slide 8: Accomplished team of biotech industry veterans and scientists committed to bringing innovation to market
Accomplished team of biotech industry veterans and scientists committed to bringing innovation to market Rivka Gluck, R.N. Marino Garcia Kristina Maximenko Ryan Savitz Edward Carr Simrat Randhawa, M.D. Susan Kalled, Ph.D. President & CEO Chief People Officer Chief Accounting Officer Head of Clinical
Slide 9: Leading life science investors and board
Leading life science investors and board $121M RAISED PRE-MERGER $70M CONCURRENT FINANCING TO MERGER BOARD OF DIRECTORS Marino Garcia Lonnie Moulder Tomas Kiselak President & CEO, Dianthus Chairman of the Board, Dianthus Managing Member, Fairmount Alison Lawton Paula Soteropoulos Jonathan Violin, Ph
Slide 10: Growing pipeline of next-generation therapeutics
Growing pipeline of next-generation therapeutics DNTH103 in ongoing Ph. 1 healthy volunteer trial, with top-line results expected in 2H’23 Pursuing validated and In-house complement and antibody Potentially multiple value-driving catalysts emerging complement targets expertise to enhance pipeline an
Slide 11: Broad opportunity remains for complement therapies to treat complement-mediated disorders
Broad opportunity remains for complement therapies to treat complement-mediated disorders Multiple complement appropriate indications; only 5 indications with FDA approved complement inhibitors DNTH103 Planned U.S. Limited innovation to improve Near-Term Indications Prevalence efficacy, safety, or c
Slide 12: gMG represents sizeable market opportunity for DNTH103
gMG represents sizeable market opportunity for DNTH103 U.S. gMG estimated addressable Soliris & Ultomiris I.V. Vyvgart sales >$5B in sales patient population: show rapid MG growth 1 Approved in gMG, aHUS, ~17 – 30K Estimated ~$5B peak sales NMOSD, PNH opportunity across multiple indications Ultomiri
Slide 13: Engineering next-generation S.C. therapeutics to target the active protein driving disease pathology
Engineering next-generation S.C. therapeutics to target the active protein driving disease pathology In the blood, there is a mix of active and inactive Current therapies do not bind selectively to the active form of the complement proteins protein, wasting a significant amount of the drug on inert
Slide 14: DNTH103 aiming to change the SoC with a potent, convenient, self-administered S.C. profile
DNTH103 aiming to change the SoC with a potent, convenient, self-administered S.C. profile Currently approved complement and FcRn inhibitors require high doses DNTH103 Target Product Profile All I.V. drugs or high-frequency S.C. pumps Potent Targets only the active form of C1s Selectivity 6500 – 750
Slide 15: DNTH103 target product profile is highly differentiated
DNTH103 target product profile is highly differentiated Need for Lower volume, less frequent, self-administered S.C. increased convenience and reduced patient burden DNTH103 More frequent and/or higher-volume S.C. Efgartigimod Rozanolixizumab Zilucoplan More frequent, higher-volume, in-clinic I.V. 1
Slide 16: DNTH103: Active C1s Inhibitor
DNTH103: ACTIVE C1S INHIBITOR A next-generation classical pathway complement inhibitor
Slide 17: Selectively inhibiting the classical pathway may offer advantages for treating severe autoimmune disorders
Selectively inhibiting the classical pathway may offer advantages for treating severe autoimmune disorders Targeting C1s preserves critical immune activity of lectin and alternative pathways, with the aim to provide a safer therapeutic option versus terminal pathway inhibitors Active form inhibited
Slide 18: C1s is a validated target to treat diseases driven by the classical complement pathway
C1s is a validated target to treat diseases driven by the classical complement pathway C1 Complex Overview C1s Role in Multiple Neuromuscular Indications • The C1 complex is the initial component of the classical • The classical pathway is the only pathway activated complement pathway by the presenc
Slide 19: Classical pathway activation is well established as a key driver of AChR+ Myasthenia Gravis
Classical pathway activation is well established as a key driver of AChR+ Myasthenia Gravis morbidity Classical Pathway Role in MG • In MG, autoantibodies target structures responsible for neuromuscular transmission at the neuromuscular junction • In AChR+ MG, this autoantibody binding triggers the
Slide 20: Myasthenia Gravis is a life-long, severe autoimmune disease with significant unmet need
Myasthenia Gravis is a life-long, severe autoimmune disease with no cure and a significant unmet need Need for new therapies that are more effective and safer, with reduced patient burden Market Disease Chronic Treatment gMG Statistics Opportunity Characteristics Paradigm • ~70K patients in the U.S.
Slide 21: DNTH103: PD activity at low concentration
DNTH103: PD activity at low concentration Potent inhibition of ex vivo antibody-triggered human red blood cell lysis demonstrated IC50* (nM) sutimlimab** 29.5 sutimlimab ravulizumab** 28.4 ravulizumab DNTH103 DNTH103 5.8 21 *Representative run. Average IC50s are comparable, but run to run variabilit
Slide 22: DNTH103: linear PK with impressive half life
DNTH103: linear PK with impressive half life DNTH103 remains in the body longer, at lower doses in NHPs At lower doses, DNTH103 has shown no evidence of target mediated clearance, remaining in the body for longer • Non-human primate half-life is ~21 days (vs. 8-12 days for a standard IgG) • Human ha
Slide 23: DNTH103 Phase 1 trial initiated in Nov'22
DNTH103 Phase 1 trial initiated in Nov’22 Trial is evaluating safety and PK/PD of DNTH103 when administered I.V. or S.C. as a single dose or multiple doses in healthy adult volunteers. Top-line data expected in 2H’23 SAD MAD I.V. Administration S.C. Administration S.C. Administration SAD 1 SAD (1 mg
Slide 24: DNTH103: Phase 1 healthy volunteer trial
DNTH103: Phase 1 healthy volunteer trial Objectives are to confirm pre-clinical evaluations: Favorable safety profile Extended half-life to enable less frequent S.C. dosing (i.e., every 2 weeks or less frequent) Potent classical pathway inhibition 23 healthy volunteers have been dosed in our Phase 1
Slide 25: DNTH103 achieves target complement inhibition via less frequent S.C. dosing
DNTH103 achieves target complement inhibition via less frequent S.C. dosing Simulation based on HV SAD S.C. data* Key Assumptions • 60-day half-life • IC90 calculated to be achieved between 80-90 ug/mL Estimated IC90 Range • 600mg S.C. on Days 1 and 2 followed by 300mg S.C. Q2W starting at Day 7 25
Slide 26: DNTH103 will target upstream, active C1s with the aim to meaningfully transform the SoC in MG
DNTH103 will target upstream, active C1s with the aim to meaningfully transform the SoC in MG DNTH103 targeted attributes C5-targeting FcRn therapies inhibitors CONSISTENT DOSING REGIMENS No on / off cycles SAFETY No FDA Boxed Warning CONVENIENCE Superior dosing and self-administration (Low-volume S
Slide 27: Steady cadence of anticipated value-driving milestones
Steady cadence of anticipated value-driving milestones Initiate Ph. 2 open-label trial in CAD to PAT I E N T D ATA I N C L A S S I C A L generate near-term patient data and exhibit PAT H W AY D R I V E N - D I S E A S E potential differentiation vs. other classical ( I N I T I AT I O N E X P E C T E
Slide 28: Exciting opportunity for next-generation complement therapies
Exciting opportunity for next- generation complement therapies DNTH103 has the potential to transform the standard of care for many severe autoimmune indications due to: ▪ MOA with clear biological rationale to treat indications driven by autoantibody activation of the complement system ▪ FDA preced
Magenta Therapeutics — Merger or Acquisition (May 2023) on 6ix